End-stage renal disease in African-American and white men: 16-year MRFIT findings

JAMA

Volumn 277, Issue 16, 1997, Pages 1293-1298

  Klag, Michael J ^a,b,e   Whelton, Paul K ^a,b   Randall, Bryan L ^c   Neaton, James D ^c   Brancati, Frederick L ^a,b   Stamler, Jeremiah ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; INCOME; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGRO; PRIORITY JOURNAL; RACE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SMOKING;

EID: 0030999998     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.16.1293     Document Type: Article

References (47)

1. US Renal Data System. USRDS 1994 Annual Data Report. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; July 1994.
2. Whittle JC, Whelton PK, Seidler AJ, Klag MJ. Does racial variation in risk factors explain black-white differences in the incidence of hypertensive end-stage renal disease? Arch Intern Med. 1991; 151:1359-1364.
3. Whelton PK, Klag MJ. Hypertension as a risk fector for renal disease: review of clinical and epidemiological evidence. Hypertension. 1989;13(suppl I):I19-I27.
4. Rostand SG, Brown G, Kirk KA, Rutsky EA, Dustan HP. Renal insufficiency in treated essential hypertension. N Engl J Med. 1989;320:384-688.
5. Brancati FL, Whittle JC, Whelton PK, Seidler AJ, Klag MJ. The excess incidence of diabetic end-stage renal disease among blacks: a population-based study of potential explanatory factors. JAMA. 1992;268:3079-3084.
6. Byrne C, Nedelman J, Luke RG. Race, socioeconomic status, and the development of end-stage renal disease. Am J Kidney Dis. 1994;23:16-22.
7. Young EW, Mauger EA, Jiang KH, Port FK, Wolfe RA. Socioeconomic status and end-stage renal disease in the United States. Kidney Int. 1993; 45:907-911.
8. Perneger TV, Whelton PK, Klag MJ. Race and end-stage renal disease: socio-economic status and access to health care as mediating factors. Arch Intern Med. 1995;155:1201-1208.
9. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13-18.
10. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA. 1982;248:1465-1477.
11. Multiple Risk Factor Intervention Trial Research Group. Design consideration in the NHLBI Multiple Risk Factor Intervention Trial (MRFIT). J Chronic Dis. 1977;30:261-275.
12. Sherwin R, Kaelber CT, Kezdi P, Kjelsberg MO, Thomas HE. The Multiple Risk Factor Intervention Trial (MRFIT), II: the development of the protocol. Prev Med. 1981;10:402-425.
13. Xeaton JD, Grimm RH, Cutler J. Recruitment of participants for the Multiple Risk Factor Intervention Trial (MRFIT). Control Clin Trials. 1988; 8:415-535.
14. Dischinger P, DuChene AG. Quality control aspects of blood pressure measurements in the Multiple Risk Factor Intervention Trial. Control Clin Trials. 1986;7(suppl 3):137-157.
15. National Institutes of Health. Lipid Research Clinics Program: Manual of Operations. Washington, DC: National Institutes of Health, US Dept of Health, Education, and Welfare; 1974:1. NIH publication 75-628.
16. Health Care Financing Administration. End-stage Renal Disease Research Report. Bethesda, Md: Health Care Financing Administration; 1987. HCFA publication 03274.
17. Wentworth DN, Neaton JD, Rasmussen WL. An evaluation of the Social Security Administration MBR file and the National Death Index in the ascertainment of vital statua. Am J Public Health. 1983;73:1270-1274.
18. International Classification of Diseases, Ninth Revision, Clinical Modification. Washington, DC: Public Health Service, US Dept of Health and Human Services; 1988.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457.
20. Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34:187-202.
21. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
22. Shulman NB, Ford CE, Hall DW, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: results from the Hypertension Detection and Follow-up Program. Hypertension. 1989;13(suppl):I80-I93.
23. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD, for the MRFIT Research Group. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial: racial and treatment effects. JAMA. 1992;268:3085-3091.
24. Tierney WM, McDonald CJ, Luft FC. Renal disease in hypertensive adults: effect of race and type II diabetes mellitus. Am J Kidney Dis. 1989;13:485-493.
25. Rosansky SJ, Hoover DR, King L, Gibson J. The association of blood pressure levels and change in renal function in hypertensive and nonhypertensive subjects. Arch Intern Med. 1990;150:2073-2076.
26. Brazy PC, Fitzwilliam JF. Progressive renal disease: role of race and antihypertensive medications. Kidney Int. 1990;37:1113-1119.
27. Perry HM Jr, Miller JP, Fornoff JR, et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension. 1995;25(pt 1): 587-594.
28. Smith GD, Neaton JD, Wentworth D, Stamler R, Stamler J. Socioeconomic differentials in mortality risk among men screened for the Multiple Risk Factor Intervention Trial, I: white men. Am J Public Health. 1996;86:486-496.
29. Smith GD, Wentworth D, Neaton JD, Stamler R, Stamler J. Socioeconomic differentials in mortality risk among men screened for the Multiple Risk Factor Intervention Trial, II: black men. Am J Public Health. 1996;86:497-504.
30. MacMahon S, Peto A, Cutler J, et al. Blood pressure, stroke, and coronary heart disease, I: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
31. Gretler DD, Fumo MT, Nelson KS, Murphy MB. Ethnic differences in circadian hemodynamic profile. Am J Hypertens. 1994;7:7-14.
32. Bianchi S, Bigazzi R, Baldari G, Sgherri G, Gampese VM. Diurnal variations of blood pressure and microalbuminuria in essential hypertension. Am J Hypertens. 1994;7:23-29.
33. Krieger N, Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodolegy. Am J Public Health. 1992;92:703-710.
34. Greenwald HP, Polissar NL, Borgatta EF, McCorkle R. Detecting survival effects of socioeconomic status: problems in the use of aggregate measures. J Clin Epidemiol. 1994;47:903-909.
35. Steenland NK, Thun MJ, Ferguson W, Port FK. Occupational and other exposures associated with male end-stage renal disease: a case/control study. Am J Public Health. 1990;80:153-159.
36. Glass GE, Watson AJ, LeDuc JW, Kelen GD, Quinn TC, Childs JE. Infection with a ratborne hantavirus in US residents is consistently associated with hypertensive renal disease. J Infect Dis. 1993;167:614-620.
37. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with use of acetaminophen, aspirin, and nonsteroidal anti-inflammatory drugs. N Engl J Med. 1994;331:1675-1679.
38. Barker DJP, Gluckman PD, Godfrey KM, et al. Fetal nutrition and cardiovascular disease in adult life. Lancet. 1993;341:938-941.
39. Statius LW, deJong PE. Sickle cell disease. In: Schreier RW, Gottschalk CW, eds. Diseases of the Kidney. Boston, Mass: Little Brown & Co Inc; 1988: 2561-2582.
40. Freedman BI, Iskandar SS, Appel RG. In-depth review: the link between hypertension and nephrosclerosis. Am J Kidney Dis. 1995;25:207-221.
41. Ferguson R, Grim CE, Opgenorth TJ. A familial risk of chronic renal failure among blacks on dialysis? J Clin Epidemiol. 1988;41:1189-1196.
42. Freedman BI, Spray BJ, Tuttle AB, Buckalew VM Jr. The familial risk of end-stage renal disease in African Americans. Am J Kidney Dis. 1993;21: 387-393.
43. Freedman BI, Espeland MA, Heise ER, et al. Racial differences in HLA antigen frequency and hypertensive renal failure. Am J Hypertens. 1991; 4:393-398.
44. Perneger TV, Brancati FL, Whelton PK, Klag MJ. Studying the causes of kidney disease in man: a review of methodologic obstacles and possible solutions. Am J Kidney Dis. 1905;25:722-731.
45. Schlessinger SD, Tankersley MR, Curtis JJ. Clinical documentation of end-stage renal disease due to hypertension. Am J Kidney Dis. 1994;23:655-660.
46. Perneger TV, Whelton PK, Klag MJ, Rossiter KA. Diagnosis of hypertensive end-stage renal disease: effect of patient's race. Am J Epidemiol. 1995; 141:10-15.
47. Perneger TV, Brancati FL, Whelton PK, Klag MJ. End-stage renal disease attributable to diabetes mellitus. Ann Intern Med. 1994;121:912-918.